Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST).
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2016
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms CONVERT
- Sponsors Novartis Pharmaceuticals
- 29 Apr 2012 Planned End Date changed from 1 Jun 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 01 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Dec 2011 New trial record